Last reviewed · How we verify
NCT06338202: MAVEN
Real-World Effectiveness of Mavacamten in Canada
trial testing Mavacamten in Obstructive Hypertrophic Cardiomyopathy (oHCM) in 115 participants. Completed in 19 December 2024.
12 November 2024
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 115 |
| Start date | 24 June 2024 |
| Primary completion | 12 November 2024 |
| Estimated completion | 19 December 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Mavacamten (MAVACAMTEN) — full drug profile →
Conditions studied
- Obstructive Hypertrophic Cardiomyopathy (oHCM) — all drugs for Obstructive Hypertrophic Cardiomyopathy (oHCM) →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Obstructive Hypertrophic Cardiomyopathy (oHCM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy.
Ferraresi B, Nenna A, Jawabra M, Corrado D, et al · · 2026 · PMID 42188073 · DOI 10.3390/jcdd13050187
Verify or expand the search:
- PubMed search for NCT06338202
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mavacamten
Trials testing the same drug.
- NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
- NCT07004972 — A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) · Phase 4 · recruiting
- NCT07383025 — Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan · recruiting
- NCT06856265 — Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardi · NA · not yet recruiting
- NCT06146660 — A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · recruiting
Other recruiting trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)
Currently open trials in the same condition.
- NCT07367724 — Ademetionine in Obstructive Hypertrophic Cardiomyopathy · Phase 2 · recruiting
- NCT07383025 — Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan · recruiting
- NCT07107373 — A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US · active not recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06338202 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06338202.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing